Posters

2024 Poster Presentations

• ASCO 2024: Polyploid Circulating Stromal Cells in Blood Identifies Invasive Solid Tumors and Prognosticates for Highly Aggressive Cancer Subtypes

• AACR 2024: Identifying and Stratifying Circulating Tumor Cell Cluster Subtypes in Metastatic Breast Cancer Patients and Evaluating their Clinical Outcomes

• AACR 2024: Monitoring prostate specific membrane antigen and androgen receptor expression on Circulating Stromal Cells in advanced prostate cancer patients and their correlation with patient response

• Polyploid Giant Cancer Cells 2024: PD-L1 Expression on Circulating Tumor Associated Macrophage Polyploids Predicts Patient Outcomes in Metastatic Breast Cancer

• Polyploid Giant Cancer Cells 2024: Polyploidization of cancer associated macrophages in blood circulation acts as a blood-based biomarker for screening invasive solid tumors

2023 Poster Presentations

• SABCS 2023: Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer

• ASCO 2023:  Sequential monitoring of tumor macrophage fusion cells in the circulation of metastatic breast cancer and their prognostic value

• ASCO 2023:  Extracellular Vesicles Budding from Stromal Macrophages from the Blood Circulating in Metastatic Non-Small Cell Lung Cancer Patients Predict Clinical Outcome

• Immunology 2023:  PD-L1 expression on circulating antigen presenting macrophages in blood predicts PFS & OS in an array of metastatic cancer types treated with PD-L1/PD-1 immunotherapies

• AACR 2023:  Micronuclei in circulating stromal cells correlates with PD-L1 expression and predicts progression in metastatic breast cancer

• AACR 2023: Tumor-macrophage fusion cells detected in the circulation of metastatic breast cancer patients is prognostic for rapid progression and death

• AACR 2023: Extracellular vesicles budding from stromal macrophages in the blood of metastatic non-small cell lung cancer patients correlates with poor survival

• AACR 2023: Peripheral blood biomarkers in Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer

2022 Poster Presentations

• AACR 2022:  Changes in Circulating Tumor Associated Cells Predicts Progression Free and Overall Survival in Metastatic TNBC Patients after Induction with the Anti-CCR5 Drug Leronlimab

• ASCO 2022:  Tracking changes in circulating stromal cells and circulating tumor cells predicts responsiveness of new line induction in metastatic breast cancer after 1 cycle of therapy

• ASCO 2022: Monitoring engorgement of phagocytic circulating stromal cells during chemo-radiotherapy induction predicts survival in unresectable stage 2/3 NSCLC

• ASCO 2022: Monitoring PD-L1 Expression on Circulating Stromal Cells in Blood Predicts PFS and OS in Metastatic NSCLC Patients Treated with PD-L1/PD-1 Immunotherapy      

• SABCS 2022: Decreases in Circulating Tumor Associated Cells Predict PFS and OS in a Pooled Analysis of Phase I Clinical Trials Using SV-BR-1-GM Therapy with or without Immune Check-Point Inhibitors in Metastatic Breast Cancer Patient

2021 Poster Presentations

• ASCO 2021: Hyper-Engorged Cancer Associated Macrophage-Like Cells in Circulation Predict for Multi-Organ Metastatic Disease in Solid Tumors

• ASCO 2021: Sequential Monitoring of PD-L1 on Circulating Stromal Cells in Blood Predicts PFS in NSCLC Patients Undergoing Immunotherapy after Definitive Chemoradiation

• EDRN 2021: Combining Automated Image Measurements, Blood Biomarkers, and Clinical Data for Improved Decisions in Diagnostic Mammography

• EDRN 2021: Enlarged Stromal Macrophages found in cancer patient blood are associated with more aggressive disease and poorer prognosis in localized stage I/II solid tumors

• EDRN 2021: Sequential Monitoring of PD-L1 on Circulating Stromal Cells Predicts Outcomes in Localized Unresectable Stage II NSCLC Treated with Immunotherapy after Definitive Chemoradiation

• AACR 2021: Cancer Associated Macrophage Like-Cells Predict Aggressive Disease in Local and Metastatic Prostate Cancers

• AACR 2021: CXCR4 expression in tumor associated circulating cells of patients with pancreatic cancer is prognostic for progression and overall survival

• AACR 2021: CCR5 upregulation in two subtypes of tumor associated circulating cells predict worse prognosis in metastatic breast cancer

2020 Poster Presentations

• AACR 2020: Expression of PD-L1 on Circulating Stromal Cells Predicts Immunotherapy Response in Unresectable Non-Small Cell Lung Carcinoma After Definitive Chemoradiotherapy

• AACR 2020: Circulating Stromal Cells in Resectable Pancreatic Cancer is Associated with High Pathological Stage and Poor Clinical Outcomes

• ASCO 2020: Circulating Stromal Cells as a Potential Blood Based Biomarker for Screening Invasive Solid Tumors

• ASCO 2020: Sequential Monitoring of Circulating Stromal Cells from Blood is Predictive of Progression in NSCLC Patients Undergoing Anti-PD-L1 Therapy after Definitive Chemoradiation Therapy

2019 Poster Presentations

• ASCO 2019: Training and validation study for sequential monitoring of CAMLs in circulation to predict ongoing progression in lung cancer patients undergoing definitive radiotherapy

• Keystone Symposium Conference: SV-BR-1-GM, a breast cancer cell line with features of dendritic cells, induces tumor regression in HLA matched Stage IV breast cancer patients

• AACR 2019: CAMLs are a circulating stromal cell subpopulation that accurately predicts resistance and progression in treatment naïve lung cancer patients receiving definitive radiotherapy

• AACR 2019: Combining circulating stromal cells with cell free DNA for increased sensitivity in profiling oncogenic mutations and indicates highly aggressive non-small cell lung cancer

• Tri-Con 2019: Changes in the type of circulating cancer associated macrophage-like cells during and after radiation therapy is associated with progression in thoracic cancers

• Tri-Con 2019: Real time monitoring of solid tumor progression using circulating stromal cells in early and late stage disease

• Tri-Con 2019: Cancer associated macrophage-like (CAMLs) cells in circulation predict progression and survival in all stages of solid tumors

2018 Poster Presentations

• ASCO 2018: Combining circulating tumor cells (CTCs) and circulating cancer associated macrophage - like cells (CAMLs) for accurately predicting responsiveness of new line therapies in late stage cancers

• AACR 2018: Real time monitoring of solid tumor progression by circulating stromal cells in early and late stage disease

• AACR 2018: Cancer associated macrophage-like (CAMLs) cells in blood predict progression and survival for all stages of solid tumors

• EDRN 2018: Cancer Associated Macrophage-Like Cells act as a blood based biomarker for the Early detection of numerous solid tumor types

• Tri-Con 2018: Cancer associated macrophage-like cells are prognostic indicators of survival in a variety of solid malignancies

2017 Poster Presentations

• AACR 2017: Multiplex phenotyping of circulating cancer associated macrophage-like cells in patients with solid tumors

• AACR 2017: Identifying, Subtyping and Classifying Tumor Associated Circulating Endothelial Cells in Solid Tumors

• Tri-Con 2017: Identifying, Subtyping and Classifying Tumor Associated Circulating Endothelial Cells in Solid Tumors

• Tri-Con 2017: Clinical Significance of Circulating Cancer Associated Macrophage-Like Cells in Patients with Solid Tumors

2016 Poster Presentations

• AACR 2016: Sequential tracking of PD-L1 expression and RAD50 induction in CTCs and circulating stromal cells of lung cancer patients during treatment with radiotherapy

• AACR 2016: Multi-biomarker subtyping of circulating tumor cells using sequential fluorescence quenching

• ISMRC 2016: Cancer associated macrophage-like cells in the early detection of solid tumors

• ISMRC 2016: Prognostic significance of mitosis in circulating tumor cells in breast cancer patients

• Tri-Con 2016: Cancer associated macrophage-like cells in the early detection of solid tumors from numerous malignancies

• Tri-Con 2016: Multi-analyte subtyping of circulating cancer derived cells for screening Immunotherapeutic targets

• Tri-Con 2016: Mitosis in circulating tumor cells and its prognostic significance in late stage breast cancer

2015 Poster Presentations

• ASCO 2015: Applying a mitotic index to circulating tumor cells and its prognostic significance: A cytological approach to patient stratification

• ASCO 2015: Cancer associated macrophage-like cells correlate with systemic therapy and pathological stage in numerous malignancies

• AVI 2015: A Cell Based Liquid Biopsy for Immunotherapeutic Drug Development

• AACR 2015: Cancer associated macrophage-like cells as a blood-based biomarker for the screening of solid tumors

• Tri-Con 2015: Cancer Associated Macrophage-Like Cells in the Blood of Cancer Patients

• Tri-Con 2015: Characterizing and Correlating CellSieve and CellSearch® CTCs by Cytometric Analysis

2014 Poster Presentations

• NIH-EDRN 2014: Cancer Associated Macrophage-like Cells in Baseline Blood Samples of Cancer Patients Indicate Malignant Disease

• NCI-NIBIB POC 2014: Isolation and Identification of Circulating Tumor Cells (CTCs) from breast and prostate cancer patients

• Tri-Con 2014: Detection of Circulating Tumor Cells in Renal Cell Carcinoma

• AACR 2014: Isolation and Identification of Disseminated Tumor Cells from Bone Marrow

• AACR 2014: Detection of Circulating Tumor Cells in Renal Cell Carcinoma